![Giuseppe Curigliano: Excited that the DESTINY-06 trial was presented at ASCO2024](https://oncodaily.com/pub/uploads/2024/06/IMG_3102-e1717526644895.jpeg)
Photo taken from Giuseppe Curigliano/LinkedIn
Jun 5, 2024, 15:33
Giuseppe Curigliano: Excited that the DESTINY-06 trial was presented at ASCO2024
Giuseppe Curigliano shared on LinkedIn:
“Excited to share that the DESTINY-06 trial was presented at ASCO2024 and received fantastic feedback from our outstanding audience!
A huge thank you to everyone who attended and supported our work in advancing cancer treatment.
Together, we’re making strides in oncology!”
Source: Giuseppe Curigliano/LinkedIn
Giuseppe Curigliano, MD, PhD, is the Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology.
He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.
Aug 11, 2024, 06:38
Aug 11, 2024, 05:36
Aug 11, 2024, 05:12
Aug 11, 2024, 04:55